Latest Updates on Hearing Loss Clinical Trials 2023: FDA Approvals, Therapies, Treatment Market Insights, and Key Players Revealed by DelveInsight | Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc., Strekin AG, Heyu (Suzhou) Pharmac

(New York, USA) DelveInsight's 'Hearing Loss Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline hearing loss therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the hearing loss pipeline domain.

To know more in detail about the Hearing Loss Pipeline Report offering, click here @ https://www.delveinsight.com/report-store/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Hearing Loss Pipeline Report
• DelveInsight's hearing loss pipeline report depicts a robust space with 35+ active players working to develop 45+ pipeline therapies for hearing loss treatment.
• leading hearing loss companies working in the treatment market are Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc., Strekin AG, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Sound Pharmaceuticals Incorporated, Novartis, Gateway Biotechnology, Inc., Decibel Therapeutics, Akouos, Acousia Therapeutics GmbH, AGTC, BridgeBio Inc., Lineage Cell Therapeutics, Inc., Rinri Therapeutics Ltd., Autifony Therapeutics, AudioCure Pharma GmbH, Anida Pharma Inc., Mogrify, Astellas Pharma Inc., Altamira Therapeutics, Myrtelle, Hoba Therapeutics, Perha Pharmaceuticals, and others.
• Some of the hearing loss drugs in different phases of development are PIPE 505, FX-322, SENS-401, OTO-413, STR001, HY01, SPI-1005, CGF166, Zonisamide, DB-OTO, AAV.103, AAV.104, DB-020, AK-OTOF, ACOU085, ACOU082, OTO-825, OTO-6XX, OTO-510, ,BBP-815, FX-345, Auditory Neuronal Cell Therapy, AC102, AP-001, AM-111, HB-097, and others are under different phases of hearing loss clinical trials.
• In September 2022, Sensorion announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) had adopted a positive opinion on Sensorion's application for Orphan Drug Designation (ODD) for its lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.
• In September 2022, Decibel Therapeutics announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to provide durable restoration of hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency.
• In July 2022, Mogrify Limited and Astellas Pharma Inc. announced that they had executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.
• In May 2022, Acousia Therapeutics GmbH announced that it would present data on the company's clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20-23, 2022.ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients.

Request a sample and discover the recent advances in hearing loss treatment drugs @ https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The hearing loss pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage hearing loss drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the hearing loss clinical trial landscape.

Hearing Loss Overview
Hearing loss is a very common medical condition that increases in frequency and severity with age. The affected population is also large, ranging from newborns to elderly patients, and is nearly universal in the 70+ age group. Sound waves arriving at the auricle, passing through the external auditory canal (EAC), and causing a vibration of the tympanic membrane are all part of normal hearing function. The vibration is then transmitted to the cochlea via the ossicles (malleus, incus, and stapes).

The most common hearing loss causes are auricle or helix abnormal formation, cerumen impaction, ear canal foreign bodies, otitis externa, ossicular chain dysfunction or fixation, and middle ear effusion. Muffling of speech and other sounds, trouble hearing consonants, avoidance of some social settings, and others are some of the common hearing loss symptoms.
Several methods, such as physical examination, general screening tests, and audiometer tests, are the most common tests used for hearing loss diagnosis.

Find out more about hearing loss treatment drugs @ https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

A snapshot of the Hearing Loss Pipeline Drugs mentioned in the report:
• STR001: Strekin
• FX 322: Frequency Therapeutics
• Arazasetron: Sensorion
• PIPE 505: Pipeline Therapeutics
• OTO 413: Otonomy
• DB OTO : Decibel Therapeutics
• And many others

Learn more about the emerging hearing loss pipeline therapies @ https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hearing Loss Therapeutics Assessment
The hearing loss pipeline report proffers an integral view of the hearing loss emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Hearing Loss Pipeline Report
• Coverage: Global
• Hearing loss Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Hearing loss Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Hearing loss Therapeutics Assessment By Route of Administration: Oral, Intratympanic
• Hearing loss Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Hearing loss Therapeutics Assessment By Mechanism of Action: Amyloid precursor protein secretase inhibitors, Stem cell stimulants, Calcineurin inhibitors, Serotonin 3 receptor antagonists, Brain derived neurotrophic factor agonists, Peroxisome proliferator-activated receptor gamma agonists, Gene transference, OTOF protein expression stimulants
• Key Hearing Loss Companies: Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc., Strekin AG, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Sound Pharmaceuticals Incorporated, Novartis, Gateway Biotechnology, Inc., Decibel Therapeutics, Akouos, Acousia Therapeutics GmbH, AGTC, BridgeBio Inc., Lineage Cell Therapeutics, Inc., Rinri Therapeutics Ltd., Autifony Therapeutics, AudioCure Pharma GmbH, Anida Pharma Inc., Mogrify, Astellas Pharma Inc., Altamira Therapeutics, Myrtelle, Hoba Therapeutics, Perha Pharmaceuticals, and others
• Key Hearing Loss Pipeline Therapies: PIPE 505, FX-322, SENS-401, OTO-413, STR001, HY01, SPI-1005, CGF166, Zonisamide, DB-OTO, AAV.103, AAV.104, DB-020, AK-OTOF, ACOU085, ACOU082, OTO-825, OTO-6XX, OTO-510, ,BBP-815, FX-345, Auditory Neuronal Cell Therapy, AC102, AP-001, AM-111, HB-097, and others

Dive deep into rich insights for new drugs for hearing loss treatment, visit @ https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Hearing Loss Pipeline Report Introduction
2. Hearing Loss Pipeline Report Executive Summary
3. Hearing Loss Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hearing Loss Clinical Trial Therapeutics
6. Hearing Loss Pipeline: Late Stage Products (Pre-registration)
7. Hearing Loss Pipeline: Late Stage Products (Phase III)
7.1. STR001: Strekin
8. Hearing Loss Pipeline: Mid Stage Products (Phase II)
8.1. FX 322: Frequency Therapeutics
9. Hearing Loss Pipeline: Early Stage Products (Phase I/II)
9.1. OTO 413: Otonomy
10. Hearing Loss Pipeline Therapeutics Assessment
11. Inactive Products in the Hearing Loss Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Hearing Loss Companies
14. Key Products in the Hearing Loss Pipeline
15. Hearing Loss Unmet Needs
16. Hearing Loss Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the hearing loss pipeline therapeutics, reach out @ https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Report:
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Chronic Pruritus Market: https://www.delveinsight.com/report-store/chronic-pruritus-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/orthotic-devices-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.